Clinical Trial Update: Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating immunogenicity, safety, reactogenicity, and persistence of an investigational RSV vaccine in adults 60 years and older; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV vaccine (investigational)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-12-21